雾化吸入异丙托溴铵对慢性阻塞性肺病支气管扩张剂量反应研究

STUDY ON THE RESPONSE OF INHALATION DOSES OF NEBULIZED IPATROPIUM BROMIDE SOLUTION IN TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

目的 :明确雾化液吸入方式对慢性阻塞性肺病 (COPD)支气管扩张剂量反应。方法 :采用随机、单盲交叉试验 ,对 3 3例稳定期COPD患者于 6个治疗日分别气道雾化液吸入 0 .0 5 ,0 .1,0 .2 ,0 .4 ,0 .6mg异丙托溴铵及安慰剂 ,最后定量雾化吸入器吸入 2 0 μg异丙托溴铵 ,观察用药后 8h一秒钟用力呼气量 (FEV1)变化。结果 :0 .4mg及 0 .6mg异丙托溴铵对FEV1以及其曲线下面积的增加作用都较其他剂量明显 ,但无显著差异 (P >0 .0 5 ) ;定量雾化吸入器吸入 2 0 μg相当于雾化液吸入 0 .0 8mg的强度。 8h内所有剂量对FEV1的作用都明显大于安慰剂 (P <0 .0 1)。结论 :异丙托溴铵对稳定期COPD患者雾化液吸入治疗最佳剂量为 0 .4mg ,定量雾化吸入器吸入 2 0 μg相当于雾化液吸入 0 .0

OBJECTIVE:To study the response of inhalation doses of nebulized ipatropium bromide solution in treatment of COPD.METHODS:The randomized,single blind,placebo controlled,crossover study was conducted in 33 patients with COPD.They were treated with a dose of 0.05,0.1,0.2,0.4,0.6 mg nebulized ipatropium bromide solution or placebo in 6 separated day after that they were treated with a standard dose of metered dose inhaler and the changes in FEV 1 after 8 hours treatment were observed.RESULTS:A maximum increase in FEV 1 and area under the curve after 8 hours of treatment were obtained at the doses of 0.4 mg and 0.6 mg of the ipatropium bromide solution and there wasno significant difference between the two.The standard dose of the ipatropium bromide inhaler equivalent to 0.08 mg of nebulized solution of the agent.CONCLUSION:The optimal dose for treatment of COPD patients was 0.4 mg ipatropium bromide solution.